Skip to main content
Cellid Co., Ltd. logo

Cellid Co., Ltd. — Investor Relations & Filings

Ticker · 299660 ISIN · KR7299660001 KO Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2023-09-11 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 299660

About Cellid Co., Ltd.

http://www.cellid.co.kr

Cellid Co., Ltd. is a research and development biotechnology company focused on immunotherapeutic vaccines. The company's activities are centered on two proprietary technology platforms: CeliVax for anti-cancer immunotherapy and an adenovirus vector platform for infectious disease vaccines. The CeliVax platform is used to develop personalized vaccines that utilize a patient's own B cells and monocytes to target specific cancer antigens. The adenovirus vector platform enables the rapid development of safe, non-replicating viral vector vaccines, with a key application being its COVID-19 vaccine candidate. Cellid's pipeline is built upon these core technologies to address unmet medical needs in oncology and virology.

Recent filings

Filing Released Lang Actions
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is explicitly marked as a '정정신고' (Amendment Report). It details adjustments to stock option quantities and exercise prices due to capital changes (유상증자). This type of filing is a standard regulatory disclosure regarding corporate capital structure and equity-based compensation, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for general capital changes).
2023-09-11 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is explicitly marked as a '정정신고' (Amendment Report). It details changes to the number of shares, exercise prices, and the list of recipients for stock options previously granted. This type of filing, which concerns changes to capital structure and equity-based compensation, falls under the category of regulatory filings regarding share-related changes.
2023-09-11 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically functions as a '정정신고' (Amendment Report) to a previously submitted filing regarding stock option grants. It details changes to the number of shares, exercise prices, and beneficiary lists. In the context of Korean corporate filings (DART system), this is a standard regulatory disclosure regarding capital structure and employee compensation instruments, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for general capital changes).
2023-09-11 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is a '정정신고' (Correction Report) regarding previously disclosed stock option grants. It details changes to the number of shares, exercise prices, and recipient lists. This type of disclosure regarding capital structure changes and employee stock options falls under the category of share issues or capital changes.
2023-09-11 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is a correction (정정신고) to a previous filing. It details the adjustment of stock option quantities and exercise prices due to capital changes (유상증자). This type of disclosure regarding stock options and capital structure changes falls under the category of share issues and capital changes.
2023-09-11 Korean
전환가액의조정
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing from a Korean company (Cellid) regarding the adjustment of the conversion price of convertible bonds (CB). This type of disclosure is a standard corporate action related to capital structure and financing instruments. Since it specifically details the adjustment of conversion prices due to a capital change (rights offering/paid-in capital increase), it falls under the 'Capital/Financing Update' category.
2023-09-11 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.